The loss after tax amounted to TSEK 10,295 (14,623).
The loss per share amounted to SEK 1.13 (1.77).
The cash flow from current operations was negative in the amount of TSEK 11,358 (13,032).
The gross margin was 31.5% (35.0%).
Electrode sales in volume decreased by 30% and reached 3,936 (5,600) units. Repeat sales of electrodes decreased by 30%.
The full year in figures
Net sales amounted to TSEK 6,859 (6,436).
The loss after tax amounted to TSEK 42,464 (53,086).
The loss per share amounted to SEK 5.00 (6.41).
The cash flow from current operations was negative in the amount of TSEK 44,180 (47,850).
The gross margin was 35.4% (34.5%).
Electrode sales grew in total by 10% and reached 16,704 (15,200) units. Repeat sales of electrodes grew by 31%.
Important events during the quarter
The Company finalised a preferential share issue which, after deduction of estimated issue costs, provided the Company with approximately MSEK 66.
Nevisense was presented as one of the top ten most important news stories within skin cancer for dermatologists at the Fall Clinical Dermatology Conference in the US.
The first Nevisense system in the US was installed with the well-known key opinion leader Darrel S. Rigel, MD and Clinical Professor of Dermatology at the New York University Medical Center.
The first presentation of data in a scientific poster by a US center occurred as a poster at the Fall Clinical meeting by Dr Ryan Svoboda, a Clinical Research Fellow at the National Society for Cutaneous Medicine.
SciBase signed a distribution contract with Skin Care Sweden AB to sell to non-specialist clinics and pharmacies in Italy. The agreement included an initial order of approx. MSEK 0.5, which was delivered during Q4, and potential for an additional MSEK 0.5 order in 2018.
The first US commercial order for Nevisense was received from a private clinic focused on self-pay patients in New York.
In the period SciBase received the first order from a customer as a result of the co-operation with the German medical technology company DermoScan
A nominating committee was appointed.
An extra general meeting was held on November 15th were a decision regarding a rights offering was made. The prospectus was published on November 20th.
Important events after the end of the period
No significant events have occurred after the end of the period.
Oct 1 - Dec 31
Jan 1 - Dec 31
THE GROUP
2017
2016
2017
2016
Net sales, SEK ths
1 886
1 935
6 859
6 436
Gross margin, %
31,5%
35,0%
35,4%
34,5%
Equity/Asset ratio, %
90,5%
90,8%
90,5%
90,8%
Net indebtness, multiple
0,11
0,10
0,11
0,10
Cash equivalents, SEK ths
110 015
84 955
110 015
84 955
Cashflow from operating activities, SEK ths
-11 358
-13 032
-44 180
-47 850
Earnings per share (before and after dilution), SEK
-1,13
-1,77
-5,00
-6,41
Shareholder's equity per share, SEK
12,69
11,19
13,63
11,19
Average number of shares, 000'
9 118
8 285
8 493
8 285
Number of shares at closing of period, 000'
16 618
8 285
16 618
8 285
Share price at end of period, SEK
7,80
19,00
7,80
25,20
Number of sold electrodes, pieces
3 936
5 600
16 704
15 200
Average number of employees
20
23
21
21
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 20, 2018.
This interim report has not been subject to review by the Company's auditors.
Contact person:
Michael Colérus, CFO
For more information, please contact: Simon Grant, CEO SciBase Phone: +46 72 887 43 99 Email: [email protected]
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.
SUNRATE, an intelligent global payment and treasury management platform has been named one of the Top 100 Cross-Border Payment Companies for 2024 by FXC Intelligence, which recognises and celebrates the most important players in the cross-border...
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press release dated October 18, 2023, it has...
Autohome Inc. ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 18th Floor Tower B, CEC Plaza, 3 Dan Ling...
Avid Controls is an authorized licensed manufacturer of the GEPC/Converteam MV3000 product line, and is dedicated to providing world-class support to customers for the entire lifespan of their equipment. The MV3000 modules provide reliable ancillary...
MikeWorldWide, a leading New York-based, independent public relations agencies with offices across the US and UK has promoted Megan Hueter to lead digital practice and created two new vice president positions to strengthen functional expertise in...
TechTarget's Enterprise Strategy Group, a leading IT analyst, research, and strategy firm, today announced the addition of Jim Frey as Principal Analyst to lead the firm's coverage of the networking market. Frey will be covering networking and...